Your browser doesn't support javascript.
Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.
Biever, Paul; Staudacher, Dawid L; Sommer, Michaela J; Triebel, Hannah; Neukamm, Merja A; Bode, Christoph; Supady, Alexander; Lother, Achim.
  • Biever P; Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Staudacher DL; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Sommer MJ; Department of Medicine II (Division of Infectious Diseases), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Triebel H; Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Neukamm MA; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Bode C; Institute of Forensic Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Supady A; Hermann Staudinger Graduate School, University of Freiburg, Freiburg, Germany.
  • Lother A; Institute of Forensic Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pharmacol Res Perspect ; 9(2): e00743, 2021 04.
Article in English | MEDLINE | ID: covidwho-1130677
Semantic information from SemMedBD (by NLM)
1. remdesivir TREATS COVID-19
Subject
remdesivir
Predicate
TREATS
Object
COVID-19
2. remdesivir TREATS COVID-19
Subject
remdesivir
Predicate
TREATS
Object
COVID-19
ABSTRACT
Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID-19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecules, including cytokines but also several therapeutic drugs. In this study, we evaluated whether remdesivir and its main active metabolite GS-441524 would be adsorbed by CytoSorb® . Serum containing remdesivir or GS-441524 was circulated in a custom-made system containing a CytoSorb® device. Concentrations of remdesivir and GS-441524 before and after the adsorber were analyzed by liquid chromatography-tandem mass spectrometry. Measurements of remdesivir in the outgoing tube after the adsorber indicated almost complete removal of remdesivir by the device. In the reservoir, concentration of remdesivir showed an exponential decay and was not longer detectable after 60 mins. GS-441524 showed a similar exponential decay but, unlike remdesivir, it reached an adsorption-desorption equilibrium at ~48 µg/L. Remdesivir and its main active metabolite GS-441524 are rapidly eliminated from the perfusate by the CytoSorb® adsorber device in vitro. This should be considered in patients for whom both therapies are indicated, and simultaneous application should be avoided. In general, plasma levels of therapeutic drugs should be closely monitored under concurrent CytoSorb® therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adenosine Monophosphate / Hemoperfusion / Alanine / COVID-19 Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2021 Document Type: Article Affiliation country: Prp2.743

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adenosine Monophosphate / Hemoperfusion / Alanine / COVID-19 Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2021 Document Type: Article Affiliation country: Prp2.743